Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts. [electronic resource]
Producer: 20170815Description: 664-72 p. digitalISSN:- 1476-5462
- Antigens, CD19 -- genetics
- Azacitidine -- pharmacology
- Bone Marrow Transplantation -- adverse effects
- Caspase 9 -- genetics
- DNA Methylation -- drug effects
- Genes, Transgenic, Suicide -- genetics
- Genetic Therapy -- methods
- Graft vs Host Disease -- etiology
- Humans
- Jurkat Cells
- Organic Chemicals -- pharmacology
- Transplantation, Homologous -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.